CHM

0.00%

1.4¢ chimeric therapeutics limited

thanks for sharing this flow - it’s very clear and my thoughts...

First 19 Last

Share
Profile

Follow
leveller

1,858 Posts.

33

19/11/22

15:20

Post #: 64871870
Share

Originally posted by GWR: ↑

I am a patient and a supporter of the company. My point is that initially there were more specific updates, for example:

22/04/21 Completion First Patient Intraventricular Cohort 44 x 10⁶ CLTX CAR T cells.

24/05/21 Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial 88 x 10⁶ CLTX CAR T cells.

8/02/22 Encouraging Data from Second Dose Cohort in Phase 1 Trial.

15/02/22 “now enrolling patients in the 3^rd dose cohort”.

Dosage and route(s) planned as:
·Cohort 1 44 x 10⁶ CLTX CAR T cells ICT.
·Cohort 2 88 x 10⁶ CLTX CAR T cells ICT and ICV.
·Cohort 3 220 x 10⁶ CLTX CAR T cells ICT and ICV.
·Cohort 4 440 x 10⁶ CLTX CAR T cells ICT and ICV.

From Capital Raise Presentation 22/02/22:

5/11/22 AGM presentation shows:

Slide 18 date references Nov 4, 2020 (with CLTX CAR Tresults).

Slide 21 shows visually the advancement of the CHM 1101 Glioblastoma Phase 1 trial as very well advanced.

Slide 22 (Next 6 - 12 months) says (in relation to CHM 1101):
·Completion of GBM Phase 1 Dose Escalation.
·Second CHM GBM Trial Site Initiation.
·First Patient Dosed CHM GBM Trial Site.
·Initiation of CHM GBM Ph. 1 A/B Trial.

Given enrollments for the 3rd dose (were announced to have) commenced in February and it has been suggested that 3rd and 4th dosages would be completed in CY22, it would be good to see some specific news between now and the end of CY22.

Expand

thanks for sharing this flow - it’s very clear and my thoughts and support are with you as a patient. Thank you again for sharing your views.

I saw the the CLTX CAR NK in the bottom right of the table and see they’ve now determined that this could be a combination to progress - that could certainly be a potent and compelling proposition. Looking forward to seeing things progress from here. They are very focused on their plans.

CHM Price at posting: 8.7¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 1 more message in this thread...

First 19 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
1.5¢	1.5¢	1.4¢	$15.87K	1.103M

Buyers (Bids)

No.	Vol.	Price($)
2	1876837	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	96056	2

View Market Depth

No.	Vol.	Price($)
2	1876837	0.014
12	2424769	0.013
5	1066816	0.012
4	697817	0.011
4	485142	0.010

Price($)	Vol.	No.
0.015	76056	1
0.016	735854	3
0.017	647827	3
0.018	1788235	5
0.019	987804	3

Last trade - 16.10pm 27/09/2024 (20 minute delay)

CHM (ASX) Chart

thanks for sharing this flow - it’s very clear and my thoughts...

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

thanks for sharing this flow - it’s very clear and my thoughts...

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News